First Hospital in Florida to pilot Wireless Patient Monitoring for Enhanced Patient Care and Safety

July 29, 2015 – Northwest Medical Center has deployed the latest advanced digital monitoring technology to deliver enhanced safety, care and peace-of-mind to patients for surgical patients. The wireless, wrist-worn device, named the ViSii® Mobile System, continuously tracks patient vital sign data and transmits the information to clinicians on-site or remotely. The ViSi Mobile System is the first body-worn monitor able to non-invasively measure core vital signs on a highly accurate, beat-to-beat basis. In addition to continuous cuffless non-invasive blood pressure (cNIBP) technology, the system continuously monitors: heart or pulse rate, electrocardiogram (ECG) or heart rhythm, blood oxygenation, respiration rate and skin temperature monitoring with ICU level accuracy. Clinicians at Northwest will be able to use the continuous data stream to identify early signs of deterioration, which could help prevent adverse events. Additionally, if a patient’s vital signs move beyond selected ranges, the system’s alarm system will warn clinicians, so the appropriate intervention can be taken. In addition to supporting safety, the system also aligns with Northwest Medical Center’s efforts to provide exceptional care to everyone every day. The lightweight device promotes mobility -- patients are able to get out of bed, walk around, shower and undergo physical therapy – all while remaining connected to clinicians. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.